Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.34USD
14 Dec 2018
Change (% chg)

$-0.12 (-4.88%)
Prev Close
$2.46
Open
$2.46
Day's High
$2.52
Day's Low
$2.30
Volume
595,288
Avg. Vol
274,950
52-wk High
$4.21
52-wk Low
$2.18

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $234.22
Shares Outstanding(Mil.): 84.55
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -0.20 -- --
ROI: -42.00 9.01 14.96
ROE: -42.26 10.15 16.52

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

UPDATE 1-U.S. FDA approves Catalyst Pharma's rare disease drug

Nov 28 The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

U.S. FDA approves Catalyst Pharma's rare disease drug

Nov 28 The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

Earnings vs. Estimates